ArticleFrontiers in neurology2025
Safety and effectiveness of a novel electric femoral artery compression device for hemostasis after femoral artery puncture.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the hemostatic efficacy of a novel electric femoral artery compression device in patients who underwent percutaneous endovascular procedure through femoral artery puncture. Methods: We retrospectively reviewed 1,086 patients treated with the electric compression device (ECD) and/or vascular closure device (VCD) for hemostasis of femoral catheterization sites. The clinical success of hemostasis and complications of femoral artery puncture site were collected and analyzed. Results: A total clinical success rate of 84.8% was achieved. Minor complications occurred in 161 of 1,086 patients (14.8%), and major complications occurred in 4 of 1,086 patients (0.4%). Combined application of ECD and VCD showed a lower rate of complications than using ECD or VCD alone in patients who underwent treatment of antiplatelet agents and anticoagulant. Conclusion: ECD is a safe and effective tool for hemostasis in femoral artery puncture site in percutaneous endovascular procedure with high clinical success and low complication rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.